These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 17381379)
1. Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379 [TBL] [Abstract][Full Text] [Related]
2. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Desai RJ; Ashton CM; Deswal A; Morgan RO; Mehta HB; Chen H; Aparasu RR; Johnson ML Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):233-40. PubMed ID: 21786364 [TBL] [Abstract][Full Text] [Related]
5. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
9. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. Svanström H; Pasternak B; Hviid A JAMA; 2012 Apr; 307(14):1506-12. PubMed ID: 22496265 [TBL] [Abstract][Full Text] [Related]
10. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314 [TBL] [Abstract][Full Text] [Related]
11. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ARB Trialists Collaboration J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417 [TBL] [Abstract][Full Text] [Related]
12. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. Eklind-Cervenka M; Benson L; Dahlström U; Edner M; Rosenqvist M; Lund LH JAMA; 2011 Jan; 305(2):175-82. PubMed ID: 21224459 [TBL] [Abstract][Full Text] [Related]